These Analysts Slash Their Forecasts On Phreesia Following Q4 Results

Phreesia, Inc. (NYSE: PHR) reported mixed Q4 results, with earnings of 2 cents per share, missing the consensus estimate of 7 cents, while sales reached $127.07 million, a 16% year-over-year increase. The company lowered its fiscal 2027 revenue guidance to $510–$520 million from $545–$559 million due to reduced visibility in pharma client spending. Following the earnings announcement, Phreesia's shares fell 28.6% to $8.14, prompting analysts to adjust their price targets significantly downward.